Avita Medical (ASX:AVH) - CEO, Mike Perry - The Market Herald
CEO, Mike Perry
Source: Avita Medical
Market Herald logo


Be the first with the news that moves the market
  • Avita Medical (AVH) increases its fourth-quarter revenue guidance thanks to the strength of its RECELL product
  • Revenue for the period so far has already come to $8.6 million, beating a previous estimate of $8.2 million
  • The total fourth-quarter figure is now expected to fall between $9.5 million and $9.2 million
  • The updated forecast reflects a 55 to 60 per cent increase compared with last year
  • Shares in Avita Medical finished trading yesterday at $5.01 each

With the prevailing strength of its RECELL System, Avita Medical (AVH) has elected to increase its fourth-quarter revenue guidance.

The regenerative medicine company's first American product, RECELL was approved by the US Food and Drug Administration (FDA) in September 2018 and is used for the treatment of acute thermal burns.

For the quarter ending June 31, 2021, Avita has so far generated $8.6 million in revenue, beating its previously revealed forecast of $8.2 million.

As a result, the total fourth-quarter figure is expected to fall between $9.5 million and $9.7 million. Of this, between $6 million and $6.2 million is expected to come from commercial sales of RECELL.

The remaining $3.5 million is anticipated to come from RECELL's association with BARDA — the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority.

The updated forecast reflects a 55 to 60 per cent increase compared with last year and a 30 to 34 per cent jump from the this quarter of the year.

"As people begin to return to normal activities after the confines of the COVID-19 pandemic, we have seen an increase in burn accidents requiring treatment with the RECELL System in burn centres across the country," chief executive Dr Mike Perry said.

The company said it intended to release its fourth quarter financial and operating results on August 25.

Shares in Avita Medical finished trading yesterday at $5.01 each.

AVH by the numbers
More From The Market Herald
BARD1 Life Sciences (ASX:BD1) - CEO, Leearne Hinch - The Market Herald

" BARD1 Life Sciences (ASX:BD1) updates the market on Q4

BARD1 Life Sciences (BD1) has reported advances across its sales, business development and commercialisation activities over the June quarter.
Incannex Healthcare (ASX:IHL) - Chief Medical Officer, Dr Sud Agarwal (centre) - The Market Herald

" Incannex Healthcare (ASX:IHL) has a progressive fourth quarter

Incannex Healthcare (IHL) has spent the fourth quarter progressing its cannabinoid pharmaceutical products and psychedelic medicine therapies.
Prescient Therapeutics (PTX) - CEO & Managing Director, Steven Yatomi Clarke - The Market Herald

" Prescient Therapeutics (ASX:PTX) advances clinical studies in June quarter

Prescient Therapeutics (PTX) has summarised its operations and cashflow for the June quarter.
Mesoblast (ASX:MSB) - Managing Director & CEO, Silviu Itescu - The Market Herald

" Mesoblast (ASX:MSB) trades lower following June quarterly report

Drug developer Mesoblast (MSB) is trading red following the release of its latest quarterly financial report.